Global Nonalcoholic Steatohepatitis Therapeutics and Diagnostics Market - Segmented by Pipeline Therapeutics, Diagnostic Techniques, Treatment Therapies, and Geography - Growth, Trends, and Forecast (2018 - 2023)

  • ID: 4557776
  • Report
  • Region: Global
  • 108 pages
  • Mordor Intelligence
1 of 4

FEATURED COMPANIES

  • AstraZeneca PLC
  • Enzo Biochem Inc.
  • Genfit Corp.
  • Gilead
  • Horizon Pharma PLC
  • Immuron
  • MORE
The global nonalcoholic steatohepatitis (NASH) therapeutics and Diagnostics market is expected to register a CAGR of 25.0% during the forecast period of 2018 -2023. This market is boosted by the growing prevalence of diabetes and obesity, and high investments for research and development, which leads to rising demand for NASH and others nonalcoholic fatty liver diseases (NAFLD) therapies in the market. As per the regional analysis, the well-established healthcare infrastructure with the high adoption rate of new technologies and increasing research activities, makes North America dominate this market.

Rising Prevalence of Diabetic and Obese Population Globally

The increasing global prevalence of diabetic and obese population particularly in the developed markets is expected to raise the NASH therapeutics and diagnostics market. An estimated 5-20% of the population accounting for nearly 15 million, shows the prevalence of NASH consuming fatty acids diet in the United States, which is driven by obesity and diabetes. In the United Kingdom, as per the Diabetes Community, 2015, over four million people were diagnosed with diabetes which represented 6% of the United Kingdom’s population, i.e., one in every 16. With that, the United Kingdom had the fifth highest rate of obesity in Europe in 2015, with nearly 25% of the population having body mass index of 30 or more. A similar trend or higher could be found in several developed countries, which raises the demand for NASH therapeutics and diagnostics market.

Other factors driving this market are the lucrative pipeline for NASH therapeutics and emergence of novel biomarkers and improvement in liver biopsy technologies.

Slow Advances in the Therapeutic Field

One of the primary hindrances for NASH therapeutics and diagnostics market is the slow advancements in the therapeutic field. According to an article published in 2015, in the Journal of Hepatology, there is no approved drug for NASH even after the 35 years of its formal description and 15 years of intense research worldwide. Although there are several drugs in the pipeline but the process of approving the drug to next phase has been slow. The wide range of multiple pathogenic mechanisms hinders the success rate of the drugs in clinical trials. Thus, restricting the growth of this market.

Another factor impeding this market is the lack of effective diagnostics for NAFLD.

North America to Dominate the Market

North America is set to dominate the market in the period from 2018 to 2023 for NASH therapeutics and diagnostics. The well-established healthcare infrastructure with high preference to research and development activities makes the United States a region with high opportunities for growth and long-term establishment for companies. With that, the large number of prevailing cases of high cholesterol and change in lifestyle plays a vital role in the growth of this market.

Key Developments in the Market
  • April 2018 - AstraZeneca licensed IONIS-AZ6-2.5-LRx, NASH drug from Ionis Pharmaceuticals, Inc. for USD 30 million.
  • December 2017 - NorthSea Therapeutics B.V. completed a EUR 25 million Series A funding for the development of icosabutate, an oral promising drug candidate for the treatment of NASH.
Major Players: ASTRAZENECA PLC, CONATUS PHARMACEUTICALS, INC., ENZO BIOCHEM, INC., GALMED PHARMACEUTICALS LTD, GENFIT CORP., GILEAD, HORIZON PHARMA PLC, IMMURON, INTERCEPT PHARMACEUTICALS, INC., AND NOVO NORDISK A/S, amongst others.

Reasons to Purchase the Report
  • Current and future of global nonalcoholic steatohepatitis therapeutics and diagnostics market outlook in the developed and emerging markets.
  • Analysis of various perspectives of the market with the help of Porter’s Five Forces Analysis.
  • The segment that is expected to dominate the market.
  • Regions that are expected to witness the fastest growth during the forecast period.
  • Identify the latest developments, market shares, and strategies employed by the major market players.
  • 3-month analyst support, along with the Market Estimate sheet (in Excel).
Customization of the Report

This report can be customized to meet your requirements. Please contact us for more information.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca PLC
  • Enzo Biochem Inc.
  • Genfit Corp.
  • Gilead
  • Horizon Pharma PLC
  • Immuron
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry

6. Market Dynamics
6.1 Drivers
6.1.1 Lucrative Pipeline for NASH Therapeutics
6.1.2 Rising Prevalence of Diabetic and Obese Population Globally
6.1.3 Emergence of Novel Biomarker Technologies and Improvement in Liver Biopsy Technologies
6.2 Restraints
6.2.1 Lack of Effective Diagnostics for Non Alcoholic Fatty Liver Disease (NAFLD)
6.2.2 Slow Advances in the Therapeutic Field
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Therapeutics
7.1.1 Phase III
7.1.1.1 Obeticholic Acid (OCA)
7.1.1.2 Aramchol (arachidyl amido cholanoic acid)
7.1.1.3 Saroglitazar
7.1.1.4 Elafibranor
7.1.1.5 Others
7.2 By Diagnostics Technqiues
7.2.1 Imaging
7.2.1.1 Ultrasonography (US)
7.2.1.2 Computed Tomography (CT)
7.2.1.3 Magnetic Resonance Imaging (MRI)
7.2.1.4 Others
7.2.2 Liver Biopsy
7.2.3 Biomarker diagnostics
7.2.3.1 Serum Biomarkers
7.2.3.2 Hepatic Fibrosis Biomarkers
7.2.3.3 Apoptosis Biomarkers
7.2.3.4 Oxidative Stress Biomarkers
7.2.3.5 Others
7.2.4 Other Diagnostics
7.3 By Treatment Therapies
7.3.1 Pharmacologic Therapy
7.3.2 Steatosis/insulin Resistance
7.3.3 Anti-Cytokines
7.3.4 Surgical Interventions
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.1.4 Rest of North America
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America

8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches

9. Key Players
9.1 AstraZeneca PLC
9.2 Conatus Pharmaceuticals, Inc.
9.3 Enzo Biochem, Inc.
9.4 Galmed Pharmaceuticals Ltd
9.5 Genfit Corp.
9.6 Gilead
9.7 Horizon Pharma PLC
9.8 Immuron
9.9 Intercept Pharmaceuticals, Inc.
9.10 Novo Nordisk A/S
*List not Exhaustive

10. Future of the Market

11. Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca PLC
  • Conatus Pharmaceuticals Inc.
  • Enzo Biochem Inc.
  • Galmed Pharmaceuticals Ltd
  • Genfit Corp.
  • Gilead
  • Horizon Pharma PLC
  • Immuron
  • Intercept Pharmaceuticals Inc.
  • Novo Nordisk A/S.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll